Ikena Oncology (NASDAQ:IKNA – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Ikena Oncology Price Performance
Shares of NASDAQ:IKNA opened at $1.29 on Tuesday. The business’s fifty day moving average price is $1.50 and its two-hundred day moving average price is $1.63. Ikena Oncology has a fifty-two week low of $1.22 and a fifty-two week high of $1.94. The stock has a market capitalization of $62.25 million, a price-to-earnings ratio of -1.05 and a beta of 0.48.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on IKNA shares. Wedbush reiterated a “neutral” rating and issued a $2.00 price target on shares of Ikena Oncology in a research report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Ikena Oncology in a research report on Monday, November 11th.
About Ikena Oncology
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Read More
- Five stocks we like better than Ikena Oncology
- How to Read Stock Charts for Beginners
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Business Services Stocks Investing
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
